ReviewHepatology (Baltimore, Md.)2019
Treatment Barriers in Portopulmonary Hypertension.
Review in Hepatology (Baltimore, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- International Liver Transplantation Society practice guideline update on portopulmonary hypertension.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026Guideline
- Broiler Ascites Syndrome as a Potential Spontaneous Animal Model for Human Pulmonary Arterial Hypertension: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Clinical aspects encountered in patients with portopulmonary hypertension.Medicine and pharmacy reports · 2025Review
- Porto-Pulmonary Hypertension and Hepato-Pulmonary Syndrome: Diagnostic Procedures and Therapeutic Management.Diagnostics (Basel, Switzerland) · 2025Review
- Article
- Clinical outcomes of upfront combination therapy for portopulmonary hypertension.International journal of cardiology. Cardiovascular risk and prevention · 2024Article
- Clinical Implications and Management of Spontaneous Portosystemic Shunts in Liver Cirrhosis.Diagnostics (Basel, Switzerland) · 2024Review
- Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies.Pulmonary therapy · 2024Article
- Portopulmonary Hypertension: An Updated Review.Transplantation direct · 2023Review
- Temporal Trends in Portopulmonary Hypertension Model for End-stage Liver Disease Exceptions and Outcomes.Transplantation direct · 2022Article
- Clinical Management and Outcomes of Patients With Portopulmonary Hypertension Enrolled in the Japanese Multicenter Registry.Circulation reports · 2022Article
- Causes and Circumstances of Death in Portopulmonary Hypertension.Transplantation direct · 2021Article
- The clinical characteristics, treatment, and survival of portopulmonary hypertension in Japan.BMC pulmonary medicine · 2021Observational
- Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.Nature reviews. Cardiology · 2021Review
- Hepatopulmonary Syndrome and Portopulmonary Hypertension: Current Status and Implications for Liver Transplantation.Current hepatology reports · 2020Article
- Portopulmonary Hypertension: From Bench to Bedside.Frontiers in medicine · 2020Review
- Pulmonary manifestations of chronic liver disease: a comprehensive review.Annals of gastroenterologyReview
- LTSI Consensus Guidelines: Preoperative Pulmonary Evaluation in Adult Liver Transplant Recipients.Journal of clinical and experimental hepatologyArticle
- Burden of pulmonary hypertension in patients with portal hypertension in the United States: a retrospective database study.Pulmonary circulationArticle
- Pulmonary Assessment of the Liver Transplant Recipient.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Portopulmonary hypertension (PoPH) is a form of pulmonary arterial hypertension (PAH) that can develop as a complication of portal hypertension. Treatment of PoPH includes PAH-specific therapies, and in certain cases, such therapies are necessary to facilitate a successful liver transplantation. A significant number of barriers may limit the adequate treatment of patients with PoPH and explain the poorer survival of these patients when compared to patients with other types of PAH. Until recently, only one randomized controlled trial has included PoPH patients, and the majority of treatment data have been derived from relatively small observational studies. In the present article, we review some of the barriers in the treatment of patients with PoPH and implications for liver transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.